Database of Positon Emission Tomography (PET) Digital Brain Exams, in 50th Age of Patients
NCT04163276 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 80
Last updated 2020-11-27
Summary
This study evaluate the interest to create a new database of PET digital brain exams in population of 50 years and over of patients. Half of patients with no abnormal brain metabolism while the other half patients with Alzheimer's disease.
Conditions
Interventions
- DIAGNOSTIC_TEST
-
18F FDG PET exam
All patients have received 18F-FDG PET/CT in nuclear medicine
Sponsors & Collaborators
-
GIE NANCYCLOTEP
collaborator OTHER -
Central Hospital, Nancy, France
lead OTHER
Principal Investigators
-
Verger Antoine, PhD · Central Hospital, Nancy, France
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-01-02
- Primary Completion
- 2020-06-06
- Completion
- 2020-10-31
Countries
- France
Study Locations
More Related Trials
-
18F-Florbetaben PET Amyloid Imaging in Case of Intermediate CSF Biology for the Diagnosis of Alzheimer's Disease : a Pilot Study
NCT02556502 ·Status: COMPLETED ·Phase: NA
-
Metabolic Cerebral Imaging in Incipient Dementia (MCI-ID)
NCT00329706 ·Status: COMPLETED ·Phase: NA
-
Isotopic Imaging for Prodromal Alzheimer's Disease
NCT01231295 ·Status: COMPLETED
-
18F-S16 PET/CT in Healthy Volunteers and Patients With Neurodegenerative Dementia
NCT03620552 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
PET Study of Cerebral Metabolism of 11C-acetoacetate and 18F-FDG in Patients Under Moderate Ketosis
NCT02409784 ·Status: COMPLETED ·Phase: NA
-
Creation of a Probabilistic Atlas of Normal Cerebral Uptake of 18F-FDG in PET/MRI.
NCT05355857 ·Status: COMPLETED ·Phase: NA
-
Discard the Curative Causes of Late Onset Epilepsy: the Role of Brain 18F-FDG PET
NCT05831371 ·Status: UNKNOWN
-
Modeling the Relationships Between Functional Connectivity and Amyloid Deposition in Alzheimer's Disease
NCT04174287 ·Status: UNKNOWN ·Phase: PHASE2
-
Study of Cerebral Glucose Metabolism in Neurodegenerative Diseases and Head Trauma
NCT06180213 ·Status: COMPLETED
-
Biodistribution, Pharmacokinetics, and Safety of F-18 THK-5351 PET in Alzheimer's Disease Patients and Healthy Subjects.(Positron Emission Tomograph )
NCT02686216 ·Status: COMPLETED ·Phase: PHASE1
-
Impact of FBB PET Amyloid Imaging in Change of Diagnosis in Patients With AD
NCT02681172 ·Status: COMPLETED ·Phase: PHASE4
-
Brain Blood Flow Studies of Language and Memory
NCT00001288 ·Status: COMPLETED
-
A Bridging Study on Efficacy and Safety of [18F]Florbetaben PET for Diagnosis of Alzheimer Disease Subjects in Chinese Population
NCT05527288 ·Status: COMPLETED ·Phase: NA
-
Health and Aging Brain Study: Health Disparities Tau Positron Emission Tomography (PET) Scan Study
NCT05076331 ·Status: UNKNOWN
-
FluoroAv45 Imaging Research-in Alzheimer's Disease
NCT01325259 ·Status: COMPLETED ·Phase: PHASE2
-
Investigation of the Serotoninergic System in Multiple System Atrophy: a Positron Emission Tomography (PET) Study
NCT01136213 ·Status: COMPLETED
-
Illiteracy and Vulnerability to Alzheimer's Disease: Evaluation of Amyloid Pathology by PET Imaging
NCT02494531 ·Status: COMPLETED ·Phase: NA
-
PET Imaging of Brain Amyloid in Normal Pressure Hydrocephalus
NCT01053312 ·Status: COMPLETED ·Phase: PHASE3
-
Positron Emission Tomography of Amyloid in Alzheimer's Disease
NCT00205621 ·Status: SUSPENDED ·Phase: PHASE1
-
Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations
NCT02676843 ·Status: COMPLETED ·Phase: PHASE2
-
PET Imaging of the Translocator Proteine Ligands (TSPO) With [18 F] DPA-714 Biomarker of NeuroInflammation in Cognitive Decline (NIDECO)
NCT02062099 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Evaluation of [18F]APN-1607 PET Uptake in Alzheimer's Disease Patients
NCT05043675 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558
NCT01217021 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Imaging of Brain Amyloid Plaques in the Aging Population
NCT00950430 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE4
-
Metabolic Characterization of Alzheimer's Disease and Frontotemporal Dementia by 23Na-MRI and FDG-PET
NCT07100470 ·Status: NOT_YET_RECRUITING ·Phase: NA